Head-To-Head Contrast: Auxilium Pharmaceuticals (AUXL) & Peregrine Pharmaceuticals (PPHM)

Auxilium Pharmaceuticals (NASDAQ: AUXL) and Peregrine Pharmaceuticals (NASDAQ:PPHM) are both small-cap biopharmaceuticals companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk and Volatility

Auxilium Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.


This table compares Auxilium Pharmaceuticals and Peregrine Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Peregrine Pharmaceuticals -23.15% -38.19% -16.66%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Auxilium Pharmaceuticals and Peregrine Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Peregrine Pharmaceuticals 0 0 1 0 3.00

Peregrine Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 121.73%. Given Peregrine Pharmaceuticals’ higher probable upside, analysts clearly believe Peregrine Pharmaceuticals is more favorable than Auxilium Pharmaceuticals.

Valuation & Earnings

This table compares Auxilium Pharmaceuticals and Peregrine Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A N/A ($3.27) -11.15
Peregrine Pharmaceuticals $57.63 million 3.53 -$28.15 million ($0.64) -7.05

Auxilium Pharmaceuticals has higher revenue, but lower earnings than Peregrine Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Peregrine Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Peregrine Pharmaceuticals beats Auxilium Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

Auxilium Pharmaceuticals Company Profile

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Peregrine Pharmaceuticals Company Profile

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply